Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Flexner

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 15, 2000
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeksC P Raines, C Flexner, E Sun, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2018
Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challengesS Swindells, M Siccardi, S E Barrett, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1991
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infectionC Flexner, P A Barditch-Crovo, D M Kornhauser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapyL Ratner, J Lee, S Tang, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2009
Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteersP A Pham, C J L la Porte, L S Lee, et al.
The American Journal of Medicine|July 1, 1996
Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapyA W Heldman, T V Hartert, S C Ray, et al.
Nature Medicine|May 6, 1999
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyD Finzi, J Blankson, J D Siliciano, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 15, 2000
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeksC P Raines, C Flexner, E Sun, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2018
Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challengesS Swindells, M Siccardi, S E Barrett, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1991
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infectionC Flexner, P A Barditch-Crovo, D M Kornhauser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapyL Ratner, J Lee, S Tang, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2009
Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteersP A Pham, C J L la Porte, L S Lee, et al.
The American Journal of Medicine|July 1, 1996
Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapyA W Heldman, T V Hartert, S C Ray, et al.
Nature Medicine|May 6, 1999
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyD Finzi, J Blankson, J D Siliciano, et al.
Pageof 7